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To combat the emergence of drug-resistant strains
of Mycobacterium tuberculosis, new antitubercular
agents and novel drug targets are needed. Pheno-
typic screening of a library of 594 hit compounds un-
covered two leads that were active againstM. tuber-
culosis in its replicating, non-replicating, and
intracellular states: compounds 7947882 (5-methyl-
N-(4-nitrophenyl)thiophene-2-carboxamide) and
7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carba-
mothioyl]propanamide). Mutants resistant to both
compounds harbored mutations in ethA (rv3854c),
the gene encoding the monooxygenase EthA, and/or
in pyrG (rv1699) coding for the CTP synthetase, PyrG.
Biochemical investigationsdemonstrated thatEthA is
responsible for the activation of the compounds, and
bymass spectrometrywe identified the activemetab-
olite of 7947882, which directly inhibits PyrG activity.
Metabolomic studies revealed that pharmacolog-
ical inhibition of PyrG strongly perturbs DNA and
RNA biosynthesis, and other metabolic processesChemrequiring nucleotides. Finally, the crystal structure of
PyrG was solved, paving the way for rational drug
design with this newly validated drug target.
INTRODUCTION
Tuberculosis (TB) remains a leading cause of infectious mortality
worldwide, killing approximately 1.5 million people each year.
Drug-resistant strains of Mycobacterium tuberculosis threaten
global TB management, with an estimated 450,000 cases being
multidrug resistant, defined as resistant to rifampin and isoni-
azid. A subset of these cases, approximately 10%, is also resis-
tant to the second-line drug classes, fluoroquinolones, and
injectable aminoglycosides, and is referred to as extensively
drug resistant (WHO, 2014).
Defining the pharmacological target(s) of antitubercular drugs
under development and finding new compounds with greater
potency are both important aspects in the search for agents
that are effective against drug-sensitive and drug-resistant
M. tuberculosis strains (Lechartier et al., 2014). Several current
antimycobacterial agents are prodrugs requiring some form of
cellular activation before they can bind to their specific targetsistry & Biology 22, 917–927, July 23, 2015 ª2015 The Authors 917
Table 1. Activity In Vitro in Latent and Replicating M. tuberculosis Growth and Activity Ex Vivo of the Two Selected Compounds
Compound ID Structure H37Rv MIC (mg/ml) ss18b IC50/IC90 (mg/ml) Intracellular IC50/IC90 (mg/ml)
7904688 0.5 2.5/20 0.175/0.625
7947882 0.5 2.5/10 0.625/1.25and, in such cases, resistance can be mediated by mutations
that prevent the activation step. Therefore, understanding the
mode of activation not only helps to decipher the mechanisms
of drug resistance, but may also facilitate the development of
analogs that do not require activation (Dover et al., 2007).
In this work, by screening a library of compounds with known
antitubercular activity, established by the National Institute of
Allergy and Infectious Diseases (NIAID) (Ananthan et al., 2009;
Goldman and Laughon, 2009; Maddry et al., 2009), a new
series of molecules was found, displaying a very low minimum
inhibitoryconcentration (MIC) value (0.5mg/ml), that includescom-
pounds 7947882 and 7904688. Through the isolation ofM. tuber-
culosis-resistantmutants, genetic validation, andbiochemical and
structural studies, the main mechanisms of activation and resis-
tance of these new antitubercular compounds have been charac-
terized. The combined data indicate that 7947882 and 7904688
are prodrugs activated by the EthA monooxygenase, which then
target PyrG, a cytidine triphosphate (CTP) synthetase catalyzing
the ATP-dependent amination of uridine triphosphate (UTP) to
form the essential pyrimidine nucleotide CTP (Long and Pardee,
1967). CTP synthetase is thus a tractable new TB drug target.
RESULTS AND DISCUSSION
Screening of NIAID Library
A library of 594 compounds, selected by high-throughput
screening (HTS) against M. tuberculosis H37Rv (Ananthan
et al., 2009; Goldman and Laughon, 2009; Maddry et al.,
2009), was tested for activity against non-replicatingM. tubercu-
losis using the streptomycin-starved 18b (ss18b) model (Sala
et al., 2010; Zhang et al., 2012). Two promising compounds
were identified: a 5-methyl-N-(4-nitrophenyl)thiophene-2-car-
boxamide (7947882) and a 3-phenyl-N-[(4-piperidin-1-ylphenyl)
carbamothioyl]propanamide (7904688). Both compounds also
showed activity against replicating and intracellular M. tubercu-
losis H37Rv (Table 1). Moreover, the molecules were not
cytotoxic to HepG2, A549, Raw, and Huh7 cell lines at concen-
trations below 40 mg/ml. Compounds were re-purchased from
Chembridge Chemical Store (http://www.hit2lead.com/) and
the results were confirmed.
Isolation and Characterization ofM. tuberculosis-
Resistant Mutants
To characterize the mechanism of action of 7947882 and
7904688, several spontaneousM. tuberculosismutants resistant918 Chemistry & Biology 22, 917–927, July 23, 2015 ª2015 The Authto the compounds were isolated. The spontaneous mutants
exhibited the same resistance levels to both drugs (10 mg/ml,
203 MIC) (Table 2). Illumina whole-genome sequencing of all
mutants revealed mutations either in ethA (rv3854c), encoding
a monooxygenase responsible for ethionamide (ETH) activation
(Baulard et al., 2000), and/or pyrG (rv1699), encoding the CTP
synthetase, which performs the ATP-dependent amination of
UTP to form CTP as the final step of the pyrimidine nucleotide
biosynthetic pathway (Endrizzi et al., 2004) (Table 2). Notably,
M. tuberculosismutants resistant to compound 7947882 carried
different point mutations in ethA, resulting in either an amino acid
substitution or a truncated protein. In addition, these mutants
all harbored the same mutation in the pyrG gene: T557G
(Val186Gly). By contrast, no mutations in ethA were found in
M. tuberculosis mutants resistant to compound 7904688, but
these all carried the Val186Gly substitution in PyrG (Table 2).
Since pyrG, unlike ethA, is predicted to be an essential gene in
M. tuberculosis (Sassetti et al., 2001), it was hypothesized that
EthA could be required to activate 7947882 and 7904688 com-
pounds, while the target of the activated metabolites might be
PyrG. The finding that all strains harboring a mutation in ethA
showed cross-resistance to ETH, whereas strains mutated
only in pyrG remained ETH sensitive, reinforced this hypothesis
(Table 2).
EthA Is an Activator of 7947882 and 7904688
Compounds
To verify whether EthA is responsible for the activation of
7947882 and 7904688, the ethA gene was cloned in the expres-
sion vector pSODIT-2, and M. tuberculosis H37Rv cells were
transformedwith the corresponding recombinant plasmid. A sta-
tistically significant shift in the MIC of the transformants was
observed with respect to the control; overexpression of ethA in
M. tuberculosis H37Rv increased the sensitivity to 7947882
and 7904688 (Table S1). Moreover, the overexpression of wild-
type ethA restored the sensitivity to 7947882 in M. tuberculosis
82.14 mutant cells, carrying a mutation in ethA (Table S1).
To prove that both compounds were activated by EthA, a re-
combinant form of the M. tuberculosis enzyme was expressed
in Escherichia coli and purified, and its activity toward the two
compounds as substrates was assayed. EthA was active toward
both 7947882 and 7904688, with kcat values of 2.9 ± 0.08 and
2.4 ± 0.15 min1 and Km values of 0.037 ± 0.002 and 0.055 ±
0.004 mM for 7947882 and 7904688, respectively. Moreover,
both compounds were better substrates for EthA than ETH,ors
Table 2. Main Features of M. tuberculosis Mutants Resistant to
7947882 and 7904688
M. tuberculosis
Strains
MIC (mg/ml)
WGS Sequencing
Results (Amino
Acid Change)
7947882 7904688 ETH ethA pyrG
H37Rv 0.5 0.5 1 – –
82.14 >40 >40 10 T133C
(W45R)
T557G
(V186G)
82.19 >40 >40 10 T386C
(L129P)
T557G
(V186G)
82.22 >40 >40 10 DT-94 T557G
(V186G)
88.7 5–10 10 0.5 – T557G
(V186G)
88.10 5–10 10 0.5 – T557G
(V186G)
81.10a >40 >40 10 D1109–
1137
–
See Table S1.
aLaboratory collection.showing 10-fold higher affinity (Km for ETH 0.34 mM), similar
to that for phenylacetone, the best EthA substrate found so far
(Km 0.06 mM and kcat 0.027 s
1) (Fraaije et al., 2004). The body
of genetic and biochemical data strongly suggests that these
two compounds are prodrugs that need EthA activation.
7947882 and 7904688 Do Not Affect PyrG Enzyme
Activity but Require EthA Activation
To check whether compounds 7947882 and 7904688 were able
to inhibit PyrG, their effect on the enzyme activity was evaluated.
For this purpose, wild-type PyrG and the V186G mutant pro-
tein were produced in E. coli, purified, and characterized.
M. tuberculosis PyrG shows catalytic constants (kcat 21.9 ±
0.5 s1 and Km 0.18 ± 0.01 mM toward ATP; kcat 22.9 ± 0.9 s
1
andKm 0.14 ± 0.01mM toward UTP) very similar to those of other
bacterial CTP synthetases (Anderson, 1983; Long and Pardee,
1967; Willemoe¨s et al., 2005). The PyrG mutant V186G was still
active, but partially impaired, displaying reduced kcat values
toward both substrates (1.5 ± 0.11 and 1.6 ± 0.08 s1 for ATP
and UTP, respectively). Moreover, the mutant enzyme showed
a Km value for ATP that was about 10-fold higher than that of
the wild-type protein (1.46 ± 0.18 mM), whereas the affinity for
UTP was unchanged.
Since this mutation is associated with resistance to 7947882
and 7904688 (Table 2), it was conceivable that the ATP-binding
site was involved in binding the inhibitors. For this reason, the
effects of the two compounds were tested on wild-type PyrG
at a final concentration of 200 mM. As expected for molecules
that need to be activated by EthA, the compounds were ineffec-
tive toward PyrG in all the conditions tested.
Thus, to confirm that EthA produces metabolites that might
act on PyrG, the EthA enzymatic reaction was performed with
either 7947882 or 7904688 in the presence of PyrG, and the ac-
tivity of the latter enzyme wasmonitored during the course of the
reaction. The blank control was performed omitting reducedChemnicotinamide adenine dinucleotide phosphate (NADPH) to hinder
the EthA-catalyzed reaction, and under these conditions PyrG
maintained full activity for up to 6 hr of incubation. By contrast,
in the presence of an actively working EthA, PyrG lost full activity
within 4 hr when incubated with 7947882, and about 80% of its
activity in 6 hr when incubatedwith 7904688 (Figures 1A and 1C).
At the end of incubation, to remove EthA as well as any un-
bound compounds, PyrG was re-purified by Ni-NTA (nitrilotri-
acetic acid) chromatography and dialyzed. Whereas PyrG
from the blank reaction preserved its activity, the enzyme incu-
bated in the full reaction remained completely inactive. More-
over, in the UV-Vis spectrum of PyrG incubated with EthA and
7947882, an additional peak appeared at 330 nm (Figure 1B).
This peak, which was not present in the PyrG spectrum from
blank reactions without NADPH, is characteristic of 7947882,
thus demonstrating that, in contrast to its prodrug, the EthA-acti-
vated metabolite is able to bind PyrG. Similarly, the spectrum of
PyrG incubated with 7904688 showed the broad peak between
310 and 400 nm, typical of the compound; this peak was absent
in the blank control (Figure 1D). These results demonstrated that
the conversion of 7947882 and 7904688 by EthA leads to active
inhibitors of PyrG.
Identification of Active Metabolites of 7947882
EthA is known to catalyze the oxygenation of the thioamide moi-
ety of ETH, leading to the formation of S-oxide and S-dioxide
products (Vannelli et al., 2002), as well as the oxygenation of
the sulfide group of methyl(p-tolyl)sulfide (Fraaije et al., 2004).
Thus, it is conceivable that EthA might catalyze a similar reaction
on the thiophene moiety of 7947882. To confirm this hypothesis,
we attempted to identify the active metabolite(s) of the 7947882
prodrug after purification from the EthA reaction mixture.
Two main products (M1 and M2) were isolated and subjected
to mass spectrometry analysis. The two isolated compounds
showed m/z values of 293 and 277, respectively, which are in
agreement with the S-dioxide and the S-monoxide derivatives
of the 7947882 compound. Moreover, the fragmentation spectra
of the metabolites showed a pattern similar to that of 7947882, in
accordance with mono- and di-oxygenation of the thiophene
sulfur atom of the substrate (Figures 1E and 1F). The partially pu-
rified metabolites were tested against PyrG protein and found to
inhibit its enzymatic activity. Notably, the M1 product showed a
higher degree of inhibition.
To better characterize the 7947882 metabolites, its S-dioxide
derivative was chemically synthesized, giving rise to compound
11426026. The mass spectrum of 11426026 showed the same
pattern as the M1 compound, confirming that M1 corresponds
to the 7947882 S-dioxide derivative (Figures 1E and 1F). There-
fore, the effects of 11426026 towardM. tuberculosis growth and
toward PyrG activity were assessed. The MIC of 11426026 for
M. tuberculosis H37Rv, ethA, and pyrG mutant strains was
determined (Table S2). Wild-type M. tuberculosis and the ethA
mutant were similarly sensitive to 11426026 (with MICs close
to that of the parent compound 7947882), showing that
11426026 does not require activation by EthA, whereas the
pyrG mutant strain was resistant, thus demonstrating that PyrG
could be the target of this active metabolite.
Indeed, this was confirmed when the inhibitory activity of
11426026 for PyrG was assessed, since the compound wasistry & Biology 22, 917–927, July 23, 2015 ª2015 The Authors 919
Figure 1. EthA Converts the 7947882 and 7904688 Compounds into Active PyrG Inhibitors
(A) Inhibition of PyrG activity during the co-incubation with EthA and 7947882. Gray bars correspond to the activities of the blank controls in the absence of
NADPH, and black bars represent the residual activities after incubation with working EthA.
(B) UV-Vis spectra of the re-purified PyrG after co-incubation with EthA reaction with 7947882 compound. Solid line is the spectrum of PyrG incubated with full
EthA reaction; dashed line is the spectrum of PyrG from blank reaction; dotted line is the spectrum of the compound at 20 mM.
(C and D) Co-incubation of PyrG with EthA and 7904688 compound. Conditions are the same as for (A) and (B), respectively.
(E and F) Identification of in vitro EthA metabolites of 7947882 compound. Mass spectrometry analysis (from top to bottom) of the 7947882 compound, the
partially purified products of EthA reaction M1 and M2, and the synthetic metabolite 11426026. (E) Full electrospray ionization mass spectrometry of the
compounds recorded in negative mode. (F) Fragmentation pattern of the compounds.
See also Figures S1 and S2; Table S2.effective against the wild-type enzyme. Interestingly, the inhibi-
tory effects were only found at subsaturating concentrations of
ATP (IC50 0.035 ± 0.002 mM in the presence of 0.2 mM ATP).
Moreover, the compound was not active against the PyrG
V186G mutant when tested under the same conditions. In fact,
the estimated IC50 value was 44-fold higher than against the
wild-type enzyme (1.5 ± 0.15 mM), at an ATP concentration of
1.5 mM, which corresponds to the Km of the mutant for this sub-
strate (Figure S1A).920 Chemistry & Biology 22, 917–927, July 23, 2015 ª2015 The AuthThis evidence confirms the hypothesis that 11426026 affects
or binds at the ATP-binding site of PyrG, behaving as a
competitive inhibitor with respect to ATP (Ki 0.010 ±
0.002 mM; Figures S1B and S1C). The high Km value of the
PyrG V186G mutant for ATP probably reflects the structural
changes resulting from the mutation, which distorts the ATP-
binding site and leading to an even lower affinity for the
11426026 derivative, thus explaining the resistance to this
compound.ors
Figure 2. PyrG Inhibition Affects Nucleotide
Metabolism in M. tuberculosis
(A) Representative EIC for the AMP ion ((M + H)+,
m/z = 348.07036) illustrating its increased pool size
in 7947882-treated M. tuberculosis (red lines)
compared with control (black lines).
(B) Heatmap illustrating overall changes in nucleo-
tide pool sizes in 7947882-treated M. tuberculosis
compared with control. Data are derived from two
biological replicates.
(C) Thin-layer chromatography of nucleotide
extract from [14C]uracil-labeled M. tuberculosis
H37Ra grown on glycerol-alanine-salts (GAS) me-
dium. The figure is a representative image from
three separate experiments.
(D) Ratio of radioactivity incorporated to [14C]UTP
and [14C]CTP. Nucleotides were extracted from
[14C]uracil-labeled M. tuberculosis H37Ra grown
onGAS, or 7H9media and separated by HPLC. The
two columns represent duplicate 2-ml samples
removed from the radiolabeled culture, processed
separately.
(E) Schematic representation of the major effects of
PyrG inhibition in mycobacteria.
See also Figure S3.The same procedure was used to identify the metabolite(s)
derived from 7904688. In this case only one metabolite was
found, corresponding to 3-phenyl-N-[(4-piperidin-1-ylphenyl)
carbamoyl]propanamide (Figure S2). This derivative likely arises
from sequential EthA reactions on the sulfur atom of the carba-
mothioyl moiety (Chigwada et al., 2014). However, this last
metabolite showed no effect on PyrG activity. It is conceivable
that the active metabolite(s) of 7904688 might be an unstable in-
termediate, thus precluding its isolation.
7947882 Inhibition of PyrG Alters Nucleotide
Metabolism in M. tuberculosis
Since PyrG is a key enzyme involved in de novo pyrimidine
biosynthesis (Meng et al., 2004), the effect of 7947882 on
M. tuberculosis nucleotide metabolism was investigated. For
this purpose, metabolomic experiments were performed with
M. tuberculosis exposed for 24 hr to 7947882 (53MIC) or its sol-
vent, DMSO. Polar metabolites were extracted and analyzed by
standard methods (de Carvalho et al., 2010; Larrouy-Maumus
et al., 2013) that focused on bases, nucleosides, and nucleo-
tides.M. tuberculosis H37Rv cells treated with 7947882 showed
a substantial increase in the abundance of all nucleotide interme-
diates that were detected. Figure 2A illustrates extracted ion
chromatograms (EIC) obtained for AMP in M. tuberculosis ex-
tracts treated with either compound or DMSO alone. Com-
pound-induced changes in abundances of the ions detected
are shown in Figure 2B. Taken together, these data demonstrate
that direct inhibition of PyrG decreased CTP levels, leading to
disruption of the nucleotide metabolic network, characterized
by increased levels of several intermediates in the biosynthesis
of pyrimidines and purines.
The molecular target of thiophenecarboxamides in mycobac-
teria was further corroborated through metabolic studies withChem[14C]uracil and the active metabolite 11426026, using M. tuber-
culosis H37Ra (MIC 4 mg/ml) grown in glycerol-alanine-salts
(GAS) medium with or without 11426026 (16 mg/ml) for 1 hr,
then [14C]uracil was added and radiolabeling continued for
3 hr. In the cells [14C]uracil is initially incorporated into
[14C]uridine monophosphate (UMP) through the action of uracil
phosphoribosyltransferase (Upp) from the pyrimidine salvage
pathway (Villela et al., 2011). This is then further metabolized to
the whole range of nucleotides and sugar nucleotides originating
from uracil. After labeling, the cells were harvested and the
nucleotide pool was extracted with diluted formic acid (Bochner
and Ames, 1982). In the pilot experiment the PyrG substrate
[14C]UTP was separated from the PyrG product [14C]CTP by
thin-layer chromatography (TLC). An autoradiograph produced
from the TLC plate clearly showed a decrease of [14C]CTP rela-
tive to [14C]UTP in treated M. tuberculosis compared with the
control (Figure 2C). To quantify the changes, the labeling
experiment was repeated under the same conditions and the
nucleotides were analyzed by high-performance liquid chroma-
tography (HPLC). Individual fractions co-eluting with the set
of standards comprising UMP, uridine diphosphate (UDP),
UTP, cytidine monophosphate, cytidine diphosphate, CTP,
UDP-Gal, UDP-GlcNAc, and UDP-MurNAc pentapeptide were
collected and quantified by measuring their radiolabel levels.
Although incorporation of radioactivity into [14C]UTP and
[14C]CTP was rather low in this experiment, the ratio of
[14C]UTP/[14C]CTP did increase in the treated culture, as ex-
pected for PyrG inhibition (Figure 2D). Higher incorporation of
[14C]uracil was achieved by using 7H9/ADC/Tween medium,
thereby confirming the trend of increased [14C]UTP/[14C]CTP
following 11426026 treatment (Figure 2D; Figure S3).
In conclusion, these experiments highlighted that inhibition of
PyrG affects nucleotide metabolism and, thus, very likely severalistry & Biology 22, 917–927, July 23, 2015 ª2015 The Authors 921
Figure 3. Essentiality of pyrG In Vitro and Ex Vivo
(A) Ten microliters of a pyrG cKD mutant suspension containing about 105 cfu
were spotted at the indicated dilutions on Middlebrook 7H10 plates
(±500 ng/ml ATc).
(B) Bacteria were grown in 7H9 medium (±500 ng/ml ATc) and diluted 1:10 in
fresh media (±500 ng/ml ATc) every 3 days. OD540 nm was recorded and used
to compile the growth curves. Each experiment was repeated at least twice.
Gray line, pyrG conditional mutant grown without ATc; black line, pyrG con-
ditional mutant grown with ATc.
(C) Growth of pyrG conditional mutant and its parental strain (control) in THP-1-
derived macrophages at an MOI of 1:20 (bacteria/macrophage). The results
are expressed as cfu per well. The reported values represent the average and
the SE obtained from two parallel independent infections. The experiment was
repeated twice using independent bacterial inocula and THP-1 cultures. ATc
(200 ng/ml) was added or not to the cell culture medium. Circles, pyrG con-
ditional mutant plus ATc; diamonds, control plus ATc; triangles, pyrG condi-
tional mutant, no ATc.
922 Chemistry & Biology 22, 917–927, July 23, 2015 ª2015 The Authaspects of mycobacterial physiology. In particular, themetabolic
changes should interfere not only with DNA and RNA biosyn-
thesis, but also with other metabolic processes that require nu-
cleotides, such as fatty acid, carbohydrate and amino acid
biosynthesis, cell wall biosynthesis, and cAMP- and c-di-AMP-
dependent signaling (Figure 2E).
Validation of PyrG Essentiality In Vivo and Ex Vivo
Since PyrG inhibition by the active metabolite of 7947882 has
been unambiguously demonstrated, its validation as a drug
target was further investigated. To show the essentiality of
pyrG in M. tuberculosis, a conditional mutant was constructed
where the pyrG promoter was replaced by the repressible pro-
moter Pptr in a strain carrying the TetR-PipOFF repressible
system (Boldrin et al., 2010). In this conditional mutant, the
expression of pyrG was expected to be downregulated by the
addition of anhydrotetracycline (ATc) to the culture medium,
thus leading to depletion of its protein product. The growth of
the pyrG conditional mutant was evaluated on solid 7H10 and
in liquid 7H9 media (± ATc, 500 ng/ml). In each case, this condi-
tional mutant exhibited inhibition of growth upon ATc exposure,
while its parental strain was not affected, thus clearly demon-
strating that PyrG is essential for M. tuberculosis growth
in vitro (Figures 3A and 3B).
PyrG essentiality was also verified during intracellular growth.
For this purpose, THP-1-derived macrophages were infected
with the pyrG conditional mutant or with its parental strain, and
the cells were incubated in the presence or absence of ATc
(200 ng/ml). While the control was able to divide intracellularly
under both conditions, the pyrG conditional mutant grew simi-
larly to the control only in the absence of ATc. When pyrG
expression was downregulated by ATc, the number of viable
bacteria dropped rapidly, demonstrating pyrG essentiality also
during intracellular growth (Figure 3C). Proof that PyrG is essen-
tial both in vitro and ex vivo further corroborates the value of this
enzyme as a drug target.
PyrG Crystal Structure
The crystal structure of PyrG was solved by molecular replace-
ment on a 2.0-A˚ resolution data set (Table S3). This structure
showed a bidomain enzyme with an N-terminal amidoligase
(ALase) domain, also commonly known as the synthetase
domain (residues 1–278), connected through an interdomain
linker (residues 279–Pro298) to a C-terminal glutamine amido-
transferase (GATase) domain (residues 299–552), both domains
displaying a Rossmann-like fold (Figure 4A). This bidomain archi-
tecture is typical of amidotransferases, already observed in the
other available structures of full-length bacterial CTP synthe-
tases (Goto et al., 2004; Endrizzi et al., 2004, 2005; Lauritsen
et al., 2011). On the other hand, the 34-residue C-terminal exten-
sion ofM. tuberculosis PyrG, which has no predicted secondary
structure or known function, could not be traced due to the lack
of supporting electron density, suggesting a high degree of
flexibility.
The enzyme, in complex with either UTP, at 2.0-A˚ resolution, or
UTP plus the non-hydrolyzable ATP analog AMP-PCP and the
glutamine analog 5-oxo-L-norleucine (3.5 A˚; Table S3), is a ho-
motetramer with crystallographic 222 symmetry (Figure 4A),
consistent with previous studies reporting positive cooperativityors
Figure 4. Crystal Structure of M. tuberculosis PyrG
(A) Tetrameric structure of M. tuberculosis PyrG in complex with nucleotides
and analogs, i.e. either UTP or UTP/AMP-PCP/L-DON. As observed in the
other available crystal structures of CTP synthetases, the N-terminal synthe-
tase domain is positioned at the center of the tetramer while the C-terminal
glutaminase domain is pointing outwards. The gray dashed line indicates the
PyrG dimers (yellow/red versus green/brown) as they can be found in the apo
structure.
(B) Surface ‘‘cut-through’’ of the synthetase active site, with UTP- and ATP-
binding pockets, and ‘‘cut section’’ that shows a possible NH4
+ channel
connecting the glutaminase to the synthetase site. The electrostatic surface
potential has been calculated and rendered by PyMol (Schroendinger, http://
www.pymol.org).
(C) Surface view of ATP-binding pocket, occupied by AMP-PCP, to show the
location of Val186 (orange) mutated in Gly in the M. tuberculosis-resistant
strains. Side chains of hydrophobic residues surrounding Val186 are depicted
as sticks.
See also Table S3; Figures S4 and S5.
Chemfor ATP and UTP due to nucleotide-driven tetramerization.
Indeed, another structure of the enzyme in the apo form at lower
resolution (3.5 A˚; Table S3), revealed a homodimeric protein,
each homodimer representing half of the functional tetramer
and showing a dimerization surface of 1,350 A˚2 per monomer
(Figure 4A), all in good agreement with previous structural
studies (Endrizzi et al., 2004, 2005; Goto et al., 2004; Lauritsen
et al., 2011). Also, consistent with the oligomeric assembly as
a dimer of dimers being triggered by ATP/UTP, the nucleotide-
binding pockets were delimited by residues from two (ATP) or
three (UTP) different subunits (Figures S4A and S4B). Surpris-
ingly, in the highest-resolution structure available (Table S3),
UTP was found lying in both pockets, a likely artifact due to the
high concentration of the nucleotide (5 mM) in the co-crystalliza-
tion conditions (Figure S4C). It should be noted that the UTP
orientation in the substrate-binding pocket is unproductive for
the course of the reaction, as the pyrimidine ring points away
from ATP. Moreover, this UTP orientation coincides with the
CTP orientation observed in E. coli PyrG in complex with CTP
and ADP (PDB: 2ad5; Figure S4C), suggesting that this structure
likely represents an inhibited enzyme (Endrizzi et al., 2005).
In contrast, in the independent crystal form, grown in the pres-
ence of AMP-PCP as well as UTP and the glutamine analog
6-diazo-5-oxo-L-norleucine (L-DON), AMP-PCP lies in the
ATP-binding site, as expected, with UTP maintaining the same
orientation as above (Figures 4B and S4B). In addition, a cova-
lent adduct was observed between the Cys393 sulfur and
oxonorleucine, as expected from the reaction with L-DON
(Hart and Powers-Lee, 2008), therefore confirming the role of
Cys393 as the catalytic nucleophile within a Gln-hydrolyzing
triad that includes His524 and Glu526 (Figures S4D and S4E).
In agreement with similar observations made on E. coli PyrG
(Endrizzi et al., 2004), a putative ammonia diffusion channel
was visualized connecting the glutaminase active site in the
C-terminal domain to the synthetase site at the N-terminal
domain (Figure 4B). However, the tunnel is not continuous, but
appears to be blocked by the side chains of residues Pro55,
Pro60, and Val66, all located on the long b2 to b3 linker that in-
cludes the short a2 (Figures S4D andS4E), forming a constriction
in the channel (Figure 4B). The residue Val186 mutated to Gly in
the M. tuberculosis-resistant mutants lies on the b7 strand
behind the conserved P loop (Gly16 to Gly25) that contributesistry & Biology 22, 917–927, July 23, 2015 ª2015 The Authors 923
Figure 5. SAR Optimization Strategy of 7947882 Compound
Modifications made on the thiophene ring (positions 4, 5 and the sulfur atom)
and the 4-nitroaniline moiety led to two more active compounds (11326028
and 11326054).
See also Tables S4 and S5.to bind the ATP phosphates, its side chain being at closest
7 A˚ from the AMP-PCP b-phosphate (Figure 4C). Despite
being located in the proximity of the ATP-binding pocket, the
Val186Gly substitution does not provide any obvious explana-
tion for the resistance profile to an ATP competitive inhibitor.
Moreover, this mutation should have a destabilizing effect on
the P loop and on its proper positioning within the ATP-binding
cleft, leading to a decreased affinity for ATP. This hypothesis,
suggested by the observation that the Val186 side chain is situ-
ated in a hydrophobic pocket delimited by Val14, Leu22
(belonging to the P loop), Leu184, Leu188, and Ile221 (Figure 4C),
is further supported by the steady-state kinetics analysis of the
V186G mutant enzyme reported above.
The availability of the M. tuberculosis PyrG structure is useful
for both structure-activity relationship (SAR) studies and
in silico docking approaches to find new PyrG inhibitors that
do not require EthA activation.
SAR Study of 7947882
To improve the antitubercular activity of 7947882, and to under-
stand the substituent requirements needed to achieve activity
againstM. tuberculosis, SAR studies were performed (Figure 5).
105 derivatives of compound 7947882 were synthesized and
tested for their activity against M. tuberculosis H37Rv. The sub-
stitutions concerned mainly the thiophene ring and the 4-nitroa-
niline moiety.
Substitution of the thiophene ring (with furan, pyrazole, or
methylthiazole) led to inactive compounds (Table S4A). The
substitution of the 4-nitroaniline led, in general, to decreased
potency of the compounds (Table S4B). The presence of the
p-nitro group was associated with the best MIC, but was not
strictly required, since its substitution with halogen atoms or a
methyl group caused only a small increase in MIC. Moreover,
the addition of further substituents to the other positions of the
phenyl ring did not improve efficacy. For instance, introduction
of bulkier substituents, such as S-methyl or sulfonamide, or the
substitution of the aniline with formimidamide derivatives, was
even detrimental for activity, as these compounds all showed a
higher MIC (Table S4B).924 Chemistry & Biology 22, 917–927, July 23, 2015 ª2015 The AuthFurthermore, no improvement arose from modification of the
substituents in the thiophene moiety. Lack of the methyl group
in position 5 of the thiophene led to an increase in the MIC (Table
S4C), as did introduction of a methyl or nitro group in position 4,
with the exception of compound 11326054 which showed a
lower MIC value (0.25 mg/ml) (Figure 5; Tables S4D and S4E).
Curiously, analogs of this compound lacking the nitro group
(11326008) did not show lower MIC (2 mg/ml). Moreover, all com-
pounds with the thiophene moiety substituted with a nitro group
showed lower potency than those lacking this group. Such high
activity of compound 11326054 is conceivably connected with
the antimycobacterial properties of nitrothiophenes (Hartkoorn
et al., 2014), and in parallel with the amide moiety discussed in
this paper.
Finally, substitution of the aniline with a hydroxy group, to give
the 5-methylthiophene-2-carboxylic acid (11326028), led to the
most potent compound (MIC of 0.128 mg/ml, Figure 5). The car-
boxylic group of compound 11326028 was fundamental for its
antimycobacterial activity, since the carboxamide derivative
was less active and, likewise for compound 7947882, modifica-
tion of the thiophene substituents led to less active derivatives
(Table S4F).
The M. tuberculosis pyrG mutant 88.7 showed levels of resis-
tance to both 11326028 and 11326054 derivatives that were
significantly higher (MIC values >8 mg/ml) compared with that
of the wild-type strain, thus confirming that they still target
PyrG. Similarly, the 81.10 mutant (mutated in ethA gene) was
resistant to both compounds, indicating that they still need to
be activated by EthA. This result was confirmed by the fact
that the compounds are substrates of the enzyme (kcat values
of 1.33 ± 0.02 min1 and 0.98 ± 0.03 min1 for 11326028 and
11326054, respectively).
Finally, five derivatives of the active EthAmetabolite 11426026
were synthesized. These compounds were all active toward
wild-type PyrG, but not against the V186G mutant. However,
none of these compounds showed an improved MIC compared
with the active metabolite of 7947882 (Table S5).
Docking of the 11426026 Active Metabolite and PyrG
Inhibitors
To acquire insight into the binding between the active metabolite
of 11426026 and PyrG, a careful computational analysis of the
possible poses of the compound was performed. Docking the
11426026 compound demonstrated that it would only success-
fully dock in the PyrG ATP site (Figures S5A, S5B and S5C). The
superimposition with the UTP molecule shows a partial overlap.
The phenyl ring is suggested to pi-stack with Arg223 while the
nitro group is proposed to interact with Ala253 and Asp252.
Similarity searching based on the 4-nitroacetanilide portion of
the molecule resulted in 12 similar compounds present in the
Collaborative Drug Discovery (CDD) database (Ekins and Bunin,
2013; Ananthan et al., 2009; Ekins et al., 2014; Maddry et al.,
2009; Reynolds et al., 2012). Four of these compounds were
tested in vitro against PyrG enzymatic activity. One compound,
CDD-823953 (LibDock score 106.7), was a weak PyrG inhibitor
(Ki = 88.9 mM). Figures S5D and S5E show how this compound
may bind less optimally in the ATP-binding site with the 4-nitro-
acetanilide portion in a different position to that seen with
11426026. Docking of compounds may be instructive for SARors
until the co-crystal structure with a ligand is obtained. For
example, the 11326054 sulfone was also docked in the PyrG
structure and was shown to be in an orientation similar to that
of the 11426026 active metabolite (Figures S5F and S5G).
SIGNIFICANCE
New leads and new targets are required for tuberculosis
drug development. Using phenotypic screening of a chemi-
cal library, two thiophenecarboxamide derivatives were
identified that inhibited M. tuberculosis under replicating,
non-replicating, and intracellular growth conditions. Both
compounds were activated by the EthA monooxygenase,
and the main metabolite of one of them (7947882), identified
bymass spectrometry, was shown to target the CTP synthe-
tase PyrG. The active metabolite was synthesized and
shown to behave as a competitive inhibitor toward the
ATP-binding site of PyrG, thus validating this enzyme as a
new antitubercular drug target. Further validation was ob-
tained genetically using conditional knockdown of pyrG to
prove its essentiality in all the physiological states. Ametab-
olomic approach demonstrated that the thiophenecarboxa-
mide derivatives caused general deregulation of nucleotide
metabolism, consistent with the inhibition of CTP synthe-
tase. The combined evidence strongly indicates that PyrG
is potentially a clinically relevant drug target. To overcome
the requirement for EthA activation, we obtained high-reso-
lution crystal structures of PyrG to underpin structure-based
drug design. This approach has already generated addi-
tional lead compounds that inhibit this new drug target
under all conditions tested.
EXPERIMENTAL PROCEDURES
NIAID Library Screening
CB2, a library of 594 compounds selected from an HTS screen on
M. tuberculosis H37Rv (Ananthan et al., 2009; Goldman and Laughon, 2009;
Maddry et al., 2009), was kindly provided by NIAID (Prof. R.C. Goldman).
These compounds were initially screened at 10 mg/ml in duplicate for activity
against H37Rv and ss18b in 96-well format, using the resazurin reduction
microtiter assay. Compounds with a percentage of inhibition of H37Rv growth
of more than 80% were subsequently analyzed for their MIC, intracellular
activity against H37Rv, and cytotoxicity against the human hepatocellular car-
cinoma cell line HepG2 and Huh7, the human lung epithelial cell line A549, and
the murine macrophage cell line RAW 264.7 (see Supplemental Experimental
Procedures).
Compounds Used and Synthesis of Their Derivatives
7904688 and 7947882 were purchased from ChemBridge Corp (http://www.
chembridge.com/index.php). Synthetic routes of thiophene derivatives,
experimental details, and compound characterization data are provided in
the Supplemental Experimental Procedures.
Isolation and Characterization ofM. tuberculosisMutants Resistant
to 7947882 and 7904688
The isolation ofM. tuberculosismutants was performed by plating 1010 cells
from an exponential growth phase wild-type culture onto 7H11 medium con-
taining different concentrations of 7947882 and 7904688, ranging from 5- to
20-fold the MIC of the wild-type strain.
Genomic DNA ofM. tuberculosis-resistant mutants and wild-type strain was
isolated and sequenced by using Illumina HiSeq2000 technology at IGA Tech-
nology Services (Udine, Italy). For the bioinformatic analysis of Illumina data,
repetitive PE and PPE gene families were discarded aswell as SNPs and indelsChemwith less than 50% probability. The mutations found in ethA (Rv3854c)
and pyrG (Rv1699) (http://tuberculist.epfl.ch/) were confirmed by Sanger
sequencing (Eurofins MWG Operon), after PCR amplification using the oligo-
nucleotides presented in the Supplemental Information. PCR products were
purified using the Wizard SV Gel and PCR Clean-Up system (Promega).
Overexpression of ethA in M. tuberculosis H37Rv
M. tuberculosis ethA was cloned into pSODIT-2, a shuttle expression vector
containing the hygromycin resistance determinant, after PCR amplification
using primers indicated in the Supplemental Information, PfuDNA Polymerase
(Promega), and genomic DNA as template. PCR fragments were digested with
BamHI and HindIII and ligated to the pSODIT-2 generating pSODIT/ethA.
M. tuberculosis H37Rv competent cells were transformed with pSODIT-2 or
pSODIT/ethA, and plated onto complete Middlebrook 7H11 agar plates
supplemented with 20 mg/ml hygromycin and different concentrations of
7947882 or 7904688, ranging from 0.125 to 20 mg/ml.
Enzyme Production and Characterization
M. tuberculosis PyrG and EthA were obtained in recombinant forms in E. coli
and purified by standard methods. Enzymatic assays were performed accord-
ing to the published methods (Fraaije et al., 2004; Lunn et al., 2008). See also
Supplemental Experimental Procedures.
Construction of aM. tuberculosis pyrG Knockdown Mutant
The first 714 bp of pyrG coding sequence was amplified using RP1609 and
RP1610 primers and cloned in the suicide plasmid pFRA170 downstream of
a Pptr-derived promoter. To replace pyrG promoter with Pptr, 10 mg of this
plasmid was used to transform TB38, an H37Rv derivative harboring the
TetR-PipOFF system in its genome at the L5 attB site (Boldrin et al., 2010).
Selection of recombinants was achieved using 7H10 agar plates containing
hygromycin (50 mg/ml). Integration of the suicide plasmid was confirmed
by PCR. Since pyrG might be co-transcribed with its downstream genes
(rv1700-rv1701), the latter genes were provided in trans on a pMV261-
derived plasmid. In this way the final pyrG conditional knockdown (cKD)
strain was obtained. This cKD strain was used for pyrG essentiality evalua-
tion in both in vitro and ex vivo experiments (see Supplemental Experimental
Procedures).
PyrG Crystallization, Data Collection, and Structure Determination
Crystallization screenings of PyrG in the presence of various ligands were
carried out at 18C by sitting drop in 96-well format (200 + 200 nl drops)
with a Mosquito dispensing robot (TTP Labtech). Crystals were identified in
several conditions. PyrG in apo form: 10% PEG8000, 200 mM Ca acetate,
100 mM HEPES (pH 7.5); complex with UTP: 17% PEG20000, 100 mM
MgCl2, 100 mM Tris-HCl (pH 8.5); complex with AMP-PCP, UTP, and
L-DON: 30% PEG2000 MME, 100 mM NaCl, 100 mM bicine (pH 9.0). All
data sets were collected on the Proxima-1 beamline at the Soleil synchrotron
(Gif-sur-Yvette, France) from single crystals at 100 K, processed with XDS
(Kabsch, 2010) and merged with Aimless from the CCP4 suite (Winn et al.,
2011). The structure was first solved by molecular replacement with the
program MOLREP (Murshudov et al., 1997) on a data set collected from a
PyrG-UTP crystal, using the structure of Thermus thermophilus CTP synthe-
tase in complex with sulfate (PDB: 1vcn; Goto et al., 2004) as the search
model. Refinement was carried out with Refmac5 (Murshudov et al., 2011)
or autoBUSTER (Bricogne et al., 2011). The other data sets were solved
by molecular replacement with MOLREP and the coordinates of a partially
refined M. tuberculosis PyrG structure as the search model. Final models
were validated through the Molprobity server (Chen et al., 2010). Docking
of PyrG inhibitors was performed as described in the Supplemental Experi-
mental Procedures.
In Vitro EthA Metabolite Production and Identification
For in vitro EthA metabolite production, 30 mg of 7947882 was incubated with
10mg of EthA in 50mMpotassium phosphate (pH 8.0), 500 mMNADPH, 10 mM
BSA, at 37C for 5 hr under agitation. To produce the PyrG-EthA metabolite
complex, the EthA reaction was performed in the presence of 45 mMPyrG. Re-
action products were purified and analyzed as described in Supplemental
Experimental Procedures.istry & Biology 22, 917–927, July 23, 2015 ª2015 The Authors 925
Metabolomic Experiments
Experimental Procedures have been described elsewhere (Larrouy-Maumus
et al., 2013; Brauer et al., 2006). In brief, M. tuberculosis H37Rv was grown
initially in 7H9 (with 0.5 g/l BSA, 0.05% tyloxapol, 0.2%glycerol, 0.2%glucose,
and 0.085% NaCl) until late logarithmic phase (OD600 = 1.0) and 1 ml was
layered onto 22-mm nitrocellulose filters (0.22 mm) under vacuum filtration.
M. tuberculosis-laden filters were placed atop 7H10 (supplemented as 7H9)
and incubated at 37C for 5 days, after which the filters were transferred to
7H10 containing 7947882 (53 MIC = 2.5 mg/ml) or the control. After 24 hr,
the bacteria were metabolically quenched by plunging M. tuberculosis-laden
filters into acetonitrile/methanol/H2O (2:2:1) pre-cooled to40C. The metab-
olites were extracted by mechanical lysing of the M. tuberculosis-containing
solution with 0.1-mm zirconia beads. Lysates were clarified by centrifugation,
filtered, and metabolites analyzed by liquid chromatography-mass spectrom-
etry as described in Supplemental Experimental Procedures.
For metabolic labeling ofM. tuberculosisH37Ra with [14C]uracil, 10 ml of the
GAS medium (Takayama et al., 1975) was inoculated in the ratio 1:100 with an
M. tuberculosis H37Ra pre-culture grown in Sauton medium. After 7 days of
static growth at 37C, the culture was split into two aliquots, and 11426026
(final concentration of 16 mg/ml) was added to one and DMSO to the other
as a control. After 1 hr, [14C]uracil (American Radiolabeled Chemicals, specific
activity 53 mCi/mmol) was added to a final concentration 1 mCi/ml. Radiolab-
eling was carried out for 3 hr, then two 2-ml batches were removed from each
culture. The bacteria were harvested by centrifugation, washed twice with a
cold physiologic solution, and immediately extracted with 110 ml of ice-cold
9% (v/v) formic acid for 30 min. The formic acid extract was recovered by
centrifugation and its radioactivity was quantified by scintillation spectrometry
in 5 ml of EcoLite scintillation liquid (MP Biomedicals). The nucleotide extract
was stored at 20C and was typically analyzed by TLC or HPLC within
24 hr (see Supplemental Experimental Procedures). Alternatively, radiolabel-
ing was performed as above with M. tuberculosis H37Ra culture grown to
OD600 = 0.375 in 7H9 medium at 37
C.
ACCESSION NUMBERS
The PDB accession numbers for coordinates and structure factors of the crys-
tal structures described here are PDB: 4ZDI (PyrG in apo form); PDB: 4ZDJ
(PyrG in complex with two molecules of UTP/Mg2+); and PDB: 4ZDK (PyrG
in complex with UTP, AMP-PCP, Mg2+, and 5-oxo-L-norleucine).
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